These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 373968)

  • 1. Communications: Should mechanisms be established for sharing among clinical trial investigators experiences in handling problems in design, execution, and analysis? Methodology: the case for improved communications.
    Meinert CL; Hawkins BS
    Clin Pharmacol Ther; 1979 May; 25(5 Pt 2):754-7. PubMed ID: 373968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Communications: Should mechanisms be established for sharing among clinical trial investigators experiences in handling problems in design, execution, and analysis? Problems of omission in communications.
    Mosteller F
    Clin Pharmacol Ther; 1979 May; 25(5 Pt 2):761-4. PubMed ID: 373970
    [No Abstract]   [Full Text] [Related]  

  • 3. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.
    Foy JM; Earls MF
    Pediatrics; 2005 Jan; 115(1):e97-104. PubMed ID: 15629972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Need to establish academic research organization for cancer clinical trial and clinical research system having clinical investigators and study coordinators, with special reference to promotion of medical and life science research policy].
    Shimoyama M
    Gan To Kagaku Ryoho; 1999 Jan; 26(2 Suppl):235-46. PubMed ID: 9987525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Research-design issues in cancer-symptom-management trials using complementary and alternative medicine: lessons from the National Cancer Institute Community Clinical Oncology Program experience.
    Buchanan DR; White JD; O'Mara AM; Kelaghan JW; Smith WB; Minasian LM
    J Clin Oncol; 2005 Sep; 23(27):6682-9. PubMed ID: 16170176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Success factors for telehealth--a case study.
    Moehr JR; Schaafsma J; Anglin C; Pantazi SV; Grimm NA; Anglin S
    Int J Med Inform; 2006; 75(10-11):755-63. PubMed ID: 16388982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Professional roles and communications in clinical placements: a qualitative study of nursing students' perceptions and some models for practice.
    Andrews GJ; Brodie DA; Andrews JP; Hillan E; Gail Thomas B; Wong J; Rixon L
    Int J Nurs Stud; 2006 Sep; 43(7):861-74. PubMed ID: 16380124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protecting research subjects under the waiver of informed consent for emergency research: experiences with efforts to inform the community.
    Shah AN; Sugarman J
    Ann Emerg Med; 2003 Jan; 41(1):72-8. PubMed ID: 12514685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. When and how to stop a clinical trial: invited remarks.
    Hamilton MT
    Clin Pharmacol Ther; 1979 May; 25(5 Pt 2):647-8. PubMed ID: 373947
    [No Abstract]   [Full Text] [Related]  

  • 13. When and how to stop a clinical trial: invited remarks.
    Chalmers TC
    Clin Pharmacol Ther; 1979 May; 25(5 Pt 2):649-50. PubMed ID: 373948
    [No Abstract]   [Full Text] [Related]  

  • 14. [Pharmacy Department standard procedures for clinical trial development].
    Pérez Peiró C; Porta Oltra B; Cholvi Llovell M; Jiménez Torres NV
    Farm Hosp; 2004; 28(1):36-47. PubMed ID: 15012177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is proper methodology associated with the use of a clinically relevant outcome measure? The case of randomized clinical trials on medical treatment of open-angle glaucoma.
    Rossetti L; Marchetti I; Orzalesi N; Scorpiglione N; Liberati A
    Online J Curr Clin Trials; 1993 Nov; Doc No 100():[6512 words; 199 paragraphs]. PubMed ID: 8305993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. When and how to stop a clinical trial: invited remarks.
    Stamler J
    Clin Pharmacol Ther; 1979 May; 25(5 Pt 2):651-4. PubMed ID: 373949
    [No Abstract]   [Full Text] [Related]  

  • 17. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current research in statistical methodology for clinical trials.
    Meier P
    Biometrics; 1982 Mar; 38 Suppl():141-53. PubMed ID: 7046819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Problems in the conduct and analysis of randomized clinical trials. Are we getting the right answers to the wrong questions?
    Rabeneck L; Viscoli CM; Horwitz RI
    Arch Intern Med; 1992 Mar; 152(3):507-12. PubMed ID: 1546913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perspectives in medicine. Generalizability of homogenous samples in clinical trials.
    Johnson MS
    J Assoc Acad Minor Phys; 1990; 1(2):31-3. PubMed ID: 2135695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.